Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206313 | 0.85 | MAPT (0.45) | ALDH1A1MAPTLMNAGAATDP1 | |
| SCHEMBL14319101 | 0.84 | HPGD (0.40) | EGFRALDH1A1MAPTLMNATDP1 | |
| SCHEMBL15800613 | 0.84 | EGFR (0.37) | EGFRALDH1A1MAPTLMNAGAA | |
| SCHEMBL30413687 | 0.82 | ALDH1A1 (0.43) | EGFRALDH1A1MAPTLMNAGAA | |
| SCHEMBL204684 | 0.82 | ALDH1A1 (0.43) | EGFRALDH1A1MAPTLMNAGAA | |
| SCHEMBL17386130 | 0.76 | EGFR (0.36) | EGFRALDH1A1MAPTLMNAGAA | |
| SCHEMBL2968528 | 0.74 | ALDH1A1 (0.53) | ALDH1A1MAPTLMNAGAAP4HB | |
| SCHEMBL562140 | 0.73 | CD274 (0.46) | FYN | |
| SCHEMBL562649 | 0.72 | CHEK1 (0.44) | ALDH1A1MAPTLMNAFYNRAB9A | |
| SCHEMBL205841 | 0.72 | MAPT (0.49) | ALDH1A1MAPTLMNAGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2743268-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-2248812-B1 | FUSED CYCLIC COMPOUNDS AS GPR40 RECEPTOR MODULATORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-25 | — | — | EP | disclosed |
| US-8598226-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-03 | — | — | US | disclosed |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8492430-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| EP-2248812-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | EGFR 1167/4885ALDH1A1 3122/4885MAPT 4546/4885 |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | EGFR 1167/4885ALDH1A1 3122/4885MAPT 4546/4885 |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | EGFR 1167/4885ALDH1A1 3122/4885MAPT 4546/4885 |
| US-20100197761-A1 | Fused cyclic compounds | GPR119, GLP1R, GPR65 | EGFR 1167/4885ALDH1A1 3122/4885MAPT 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.